NPR1

NPR1 Full Name

Non-inducible immunity protein 1

NPR1 Introduction

NPR1 (natriuretic peptide receptor 1), also known as NPR-A, is a membrane-bound guanylate cyclase receptor that plays a central role in maintaining cardiovascular and fluid homeostasis. For many patients suffering from hypertension or early-stage heart dysfunction, the underlying problem often lies in dysregulated natriuretic peptide signaling, where the body's natural ability to reduce vascular pressure becomes insufficient. NPR1 serves as the primary receptor for atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), converting extracellular hormonal signals into intracellular cGMP production. Structurally, it contains a key kinase homology domain that requires precise phosphorylation of specific serine and threonine residues for full activation. Once activated, NPR1 triggers downstream signaling that promotes vasodilation, natriuresis, and diuresis, forming a core protective axis against excessive blood volume and elevated blood pressure.

Functionally, NPR1 is tightly regulated to prevent overstimulation or signal exhaustion during prolonged cardiovascular stress. Its activation leads to increased intracellular cyclic GMP (cGMP), a second messenger that directly relaxes vascular smooth muscle and reduces cardiac preload and afterload. However, desensitization mechanisms such as receptor dephosphorylation can limit sustained activity, which becomes clinically relevant in chronic disease states where patients experience persistent fluid overload and vascular stiffness. Genetic studies have further revealed that specific NPR1 variants can significantly alter cGMP generation capacity, meaning some individuals are biologically predisposed to higher blood pressure or reduced vascular responsiveness. These functional variations help explain why standard antihypertensive therapies may be less effective in certain patient populations.

Clinically, NPR1 has emerged as a high-value therapeutic target in hypertension and heart failure, where current treatments often fail to fully control venous congestion and pressure overload. Patients with heart failure typically show elevated natriuretic peptide release, yet receptor signaling can become insufficient or dysregulated, contributing to disease progression. Experimental and early clinical research on NPR1 agonists, including monoclonal antibody-based activators, has demonstrated promising effects in reducing vascular pressure and improving hemodynamic stability, particularly by lowering venous pressure without excessive diuresis. These findings highlight a major unmet need: developing long-acting, selective NPR1 activators that can restore physiological signaling balance. As cardiovascular disease continues to rise globally, NPR1 represents a critical translational bridge between genetic susceptibility, impaired endogenous peptide signaling, and next-generation targeted therapies aimed at restoring vascular and cardiac homeostasis.

Alternate Names for NPR1

Regulatory protein NPR1; BTB/POZ domain-containing protein NPR1; Non-inducible immunity protein 1; Nim1; Nonexpresser of PR genes 1; Salicylic acid insensitive 1; Sai1; NIM1; SAI1; At1g64280; F15H21.6

• 1.Della Corte V, et al.; The Natriuretic Peptide System: A Single Entity, Pleiotropic Effects. Int J Mol Sci. 2023, 24(11):9642.
  2.Dunn ME, et al.; Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone. Nature. 2024, 633(8030):654-661.